Features | Partner Sites | Information | LinkXpress
Sign In
JIB
GLOBETECH PUBLISHING
GLOBETECH PUBLISHING

Business

Partnership Established to Decode Bowel Disease

23andMe, a personal genetics company, is collaborating with Pfizer, in which the companies will seek to enroll 10,000 people with inflammatory bowel disease in a research project designed to explore the genetic factors associated with the onset, progression, severity, and response to treatments for IBD.  More...
25 Aug 2014

Biotechnology Merger to Spur Development of a Gene Therapy Approach for Treatment of Congestive Heart Failure

Rapid improvement in the treatment of congestive heart failure is expected following the acquisition of InoCard, a German early-stage biotechnology company by uniQure, a Dutch leader in the field of gene therapy.  More...
24 Aug 2014

Global Computational Biology Sector Expected to Reach over USD 4 Billion by 2020

The global market for computational biology is expected to reach USD 4.285 billion by 2020 growing at a compound annual growth rate of 21.1%, according to new market research.  More...
17 Aug 2014

Theraclone Partners with Gilead Sciences for Neutralizing HIV Antibody Technology

Theraclone Sciences, a therapeutic antibody discovery and development company, has entered into an agreement with Gilead Sciences, under which Gilead received an exclusive license to develop and commercialize products integrating Theraclone’s broadly neutralizing HIV-antibodies for therapeutic applications in HIV.   More...
13 Aug 2014

Cancer Immunotherapy Sector Predicted to Surge to USD 9 Billion Across Major Pharma Through 2022

The immunotherapy market will experience substantial growth through 2022, increasing from USD 1.1 billion in 2012 to nearly USD 9 billion in 2022 in the United Kingdom, United States, France, Germany, Italy, Spain, and Japan, according to recent market research.   More...
30 Jul 2014

Abbott Selling Developed Market Generics Portfolio

Abbott Laboratories has sold its developed market generic drugs business to Mylan in a deal worth USD 5.3 billion.  More...
29 Jul 2014

IDT Acquires SURVEYOR Nuclease Product Line from Transgenomic

The SURVEYOR line is to be used by Integrated DNA Technologies primarily to support researchers performing mutation detection and potentially-clinical genome editing, and by Transgenomic primarily to support diagnostic and other clinical applications.  More...
13 Jul 2014


BioResearch Industry News channel updates the reader on mergers and takeovers, on cooperative agreements and on trends in the biotech industry worldwide.
 
Copyright © 2000-2014 Globetech Media. All rights reserved.